

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
27 February 2025 (27.02.2025)



(10) International Publication Number  
**WO 2025/040199 A2**

(51) International Patent Classification:  
A23L 33/135 (2016.01) A23L 33/17 (2016.01)

(21) International Application Number:  
PCT/CN2024/132347

(22) International Filing Date:  
15 November 2024 (15.11.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
202410620762.5 17 May 2024 (17.05.2024) CN

(71) Applicants: **PEKING UNIVERSITY** [CN/CN]; No. 38 Xueyuan Rd., Haidian District, Beijing 100191 (CN). **PEKING UNIVERSITY THIRD HOSPITAL** [CN/CN]; No. 49 North Garden Rd., Haidian District, Beijing 100191 (CN). **SHANGHAI MENGNIU BIOTECHNOLOGY R&D CO., LTD.** [CN/CN]; 3rd Floor, No. 665 Zhangjiang Rd., (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 201203 (CN).

(72) Inventors: **JIANG, Changtao**; 3rd Floor, No. 665 Zhangjiang Rd., (Shanghai) Pilot FreeTrade Zone, Pudong New Area, Shanghai 201203 (CN). **QIAO, Jie**; 3rd Floor, No. 665 Zhangjiang Rd., (Shanghai) Pilot FreeTrade Zone, Pudong New Area, Shanghai 201203 (CN). **WEN, Yongping**; 3rd Floor, No. 665 Zhangjiang Rd., (Shanghai) Pilot FreeTrade Zone, Pudong New Area, Shanghai 201203 (CN). **ZHANG, Xuguang**; 3rd Floor, No. 665 Zhangjiang Rd., (Shanghai) Pilot FreeTrade Zone, Pudong New Area, Shanghai 201203 (CN). **PANG, Yanli**; 3rd Floor, No. 665 Zhangjiang Rd., (Shanghai) Pilot FreeTrade Zone, Pudong New Area, Shanghai 201203 (CN). **WANG, Kai**; 3rd Floor, No. 665 Zhangjiang Rd., (Shanghai) Pilot FreeTrade Zone, Pudong New Area, Shanghai 201203 (CN). **MAO, Yuejian**; 3rd Floor, No. 665 Zhangjiang Rd., (Shanghai) Pilot FreeTrade Zone, Pudong New Area, Shanghai 201203 (CN). **LIN, Jun**; 3rd Floor, No. 665 Zhangjiang Rd., (Shanghai) Pilot FreeTrade Zone, Pudong New Area, Shanghai 201203 (CN).

(74) Agent: **LIU, SHEN & ASSOCIATES**; 10th Floor, Building 1, 10 Caihefang Road, Haidian District, Beijing 100080 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- upon request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a)
- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: USE OF CONJUGATED CHOLIC ACID TRPCA AND A STRAIN PRODUCING THE SAME FOR TREATING AND PREVENTING A METABOLIC DISEASE

(57) Abstract: Provided is the use of a conjugated cholic acid, tryptophan-conjugated bile acids (TrpCA) or a TrpCA-producing strain for preventing and/or treating a metabolic disease. The present disclosure relates to the use of tryptophan-conjugated cholic acid or its producing bacteria strain in the preparation of a composition for preventing and/or treating a metabolic disease, or for promoting GLP-1 and/or insulin production. The inventors have discovered for the first time that the tryptophan-conjugated cholic acid can significantly promote the secretion of GLP-1 in both in vivo animal model and in vitro cell model, thereby reducing weight, lowering blood glucose and relieving symptoms of non-alcoholic fatty liver disease. Moreover, colonization of the selected probiotics can also have the same metabolic improvement effects.



WO 2025/040199 A2